467 related articles for article (PubMed ID: 19667589)
1. Meeting the challenge of antibiotic resistance: The PROTEKT US study.
Stratton CW
Postgrad Med; 2002 Sep; 112(3 Suppl):7-11. PubMed ID: 19667589
[TBL] [Abstract][Full Text] [Related]
2. Increased bacterial resistance: PROTEKT US--an update.
Rybak MJ
Ann Pharmacother; 2004 Sep; 38(9 Suppl):S8-S13. PubMed ID: 15226488
[TBL] [Abstract][Full Text] [Related]
3. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update.
Karchmer AW
Clin Infect Dis; 2004 Sep; 39 Suppl 3():S142-50. PubMed ID: 15546109
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
Brown SD; Rybak MJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
[TBL] [Abstract][Full Text] [Related]
5. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
6. Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Pfaller MA; Jones RN
Postgrad Med; 2001 Feb; 109(2 Suppl):10-21. PubMed ID: 19667553
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
Doern GV; Brown SD
J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1-5 (1999-2004).
Cantón R; Unal S; Farrell DJ
Int J Antimicrob Agents; 2007 Dec; 30(6):546-50. PubMed ID: 17931834
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001.
Waites K; Brown S
South Med J; 2003 Oct; 96(10):974-85. PubMed ID: 14570341
[TBL] [Abstract][Full Text] [Related]
10. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
11. What can PROTEKT tell us at a local level?
Inoue M
J Chemother; 2002 Jul; 14 Suppl 3():17-24. PubMed ID: 12418557
[TBL] [Abstract][Full Text] [Related]
12. Barriers to the effective management of respiratory tract infections in the community.
Saginur R
Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
14. Get a handle on resistance before it gets a handle on you: the PROTEKT US Surveillance Study. Prospective Resistant Organism Tracking and Epidemiology for Ketolide Telithromycin.
Stratton CW
South Med J; 2001 Sep; 94(9):891-2. PubMed ID: 11592749
[No Abstract] [Full Text] [Related]
15. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
16. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
Pell DM
Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
[No Abstract] [Full Text] [Related]
17. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.
Farrell DJ; File TM; Jenkins SG
J Clin Microbiol; 2007 Feb; 45(2):290-3. PubMed ID: 17093012
[TBL] [Abstract][Full Text] [Related]
18. Global surveillance through PROTEKT: the first year.
Grüneberg RN
J Chemother; 2002 Jul; 14 Suppl 3():9-16. PubMed ID: 12418556
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
Felmingham D; Farrell DJ; Reinert RR; Morrissey I
J Infect; 2004 Jan; 48(1):39-55. PubMed ID: 14667791
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.
Brown SD; Farrell DJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i23-9. PubMed ID: 15265833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
